Table 1.
Demographic and clinical features of the enrolled patients. Anamnestic and hospital admission variables in the total study population (82 patients), subgroup of subjects with impaired flow-mediated dilation (FMD ≤ 7%), and patients with normal values of FMD (51 patients). The last two columns on the right show the p value derived from univariate analysis and the p value derived from binary logistic regression comparing the two mentioned subgroups. The significant correlation between both demographic and clinical feature and FMD impairment was reported in bold.
| Variable | Total Population (82 Pts) |
Impaired FMD (31/82 Pts) |
Normal FMD (51 Pts) |
p Univariate | p Regression |
|---|---|---|---|---|---|
| ANAMNESTIC DATA | |||||
| Age (years) | 52.9 ± 13.5 | 60.12 ± 11.9 (55.9–64.3) | 48.2 ± 12.6 (45.0–51.9) | <0.001 | 0.048 |
| Sex | M = 48/82 (58.5%) | 21/31 (67.7%) | 27/51(52.9%) | 0.18 | 0.411 |
| Systemic arterial hypertension | 19/82 (23.2%) | 13/31 (41.9%) | 6/51 (11.76%) | 0.002 | 0.417 |
| Diabetes | 36/82 (43.9%) | 18/31 (58.1%) | 18/51 (35.3%) | 0.04 | 0.046 |
| Autoimmune diseases | 21/82 (25.6%) | 7/31 (22.58%) | 14/51 (27.45%) | 0.62 | 0.211 |
| BMI score | 25.7 ± 4.3 | 25.5 ± 4.0 (24.0–26.9) | 25.7 ± 4.6 (24.5–27.0) | 0.78 | |
| BMI > 30 | 8/82 (9.7%) | 1/31 (3.2%) | 7/51 (13.7%) | 0.12 | 0.514 |
| Chronic kidney disease | 8/82 (9.8%) | 5/31 (16.1%) | 3/51 (5.9%) | 0.08 | 0.324 |
| Cognitive impairment | 7/82 (8.5%) | 4/31 (12.9%) | 3/51 (5.9%) | 0.12 | 0.731 |
| ADMISSION DATA | |||||
| Hydroxychloroquine | 57/82 (69.5%) | 25/31 (80.6%) | 32/51 (62.7%) | 0.09 | |
| Lopinavir + Ritonavir | 27/82 (32.9%) | 13/31 (41.9%) | 14/51 (27.5%) | 0.17 | 0.24 |
| Darunavir + Ritonavir | 35/82 (42.7%) | 14/31 (45.2%) | 21/51 (41.2%) | 0.72 | 0.36 |
| Heparin | 28/82 (34.1%) | 11/31 (35.5%) | 17/51(33.3%) | 0.84 | |
| Azithromycin | 33/82 (40.2%) | 14/31 (45.2%) | 14/51 (27.4%) | 0.10 | |
| Antiplatelet therapy | 6/82 (7.31%) | 4/31 (12.9%) | 2/51 (3.9%) | 0.12 | |
| Corticosteroids | 4/82 (4.87%) | 1/31 (3.2%) | 3/51 (5.8%) | 0.59 | |
| ICU admission | 9/82 (10.9%) | 5/31 (16.1%) | 4/51 (7.8%) | 0.62 | 0.581 |
| Oxygen therapy | 33/82 (40.2%) | 14/31 (45.2%) | 19/51 (37.3%) | 0.49 | 0.612 |
| Non-invasive ventilation | 11/82 (13.4%) | 4/31 (12.9%) | 7/51 (13.7%) | 0.93 | 0.866 |
| Invasive ventilation | 4/82 (4.9%) | 2/31 (6.5%) | 2/51 (3.9%) | 0.76 | 0.643 |
| Pulmonary embolism | 2/82 (2.4%) | 1/31 (3.2%) | 1/51 (2%) | 0.88 | |
| Venous thrombosis | 2/82 (2.4%) | 2/31 (6.5%) | 0/51 (0%) | 0.19 | |
BMI = body mass index; FMD = flow-mediated dilation; ICU = intensive care unit.